SOM Biotech closed €2M funding round on January 2017 where 18 international investors from 10 different countries participated such as Monaco, Poland, UK, USA, India and South Korea among others.

Most of the super-business angels involved include former pharmaceutical executives, which shows trust in SOM’s business model and its future vision.

Additionally, SOM Biotech opened a €10M Series A round during JP Morgan Healthcare Conference in San Francisco on January 2017.

These funds will allow SOM Biotech to increase its presence in the USA market, foster the license-out of its assets and co-development efforts with other pharmaceutical companies in the sector. Moreover, the funds will be allocated to the completion of 2 Phase 2a clinical trials for SOM3355 to treat Huntington’s disease and SOM1201 for the treatment of Adrenoleucodystrophy.

Since SOM Biotech was established at the end of 2009 more than €5.3M from public and private sector has been raised.

Would you like to invest this unique opportunity?






    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.